Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Immune checkpoint inhibitors (ICI) have emerged as a remarkable treatment option for
diverse cancer types. Currently, ICIs are approved for an expanding array of cancer …

Background Hepatocellular carcinoma (HCC) ranks the fourth in terms of cancer-related
mortality globally. Herein, in this research, we attempted to develop a novel immune-related …

Background Radioimmunotherapy has a promising antitumor effect in hepatocellular
carcinoma (HCC), depending on the regulatory effect of radiotherapy on tumor immune …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world
and its incidence is increasing in many countries. In recent years, with the deepening …

Several immune checkpoint blockades (ICBs) capable of overcoming the
immunosuppressive roles of the tumor immune microenvironment have been approved by …

Background: Several strategies based on immune checkpoint inhibitors (ICIs) have been
developed for cancer therapy, opening to advantages in cancer outcomes. However, several …

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and it
has diverse etiologies with multiple mechanisms. The diagnosis of HCC typically occurs at …

The emergence of immune checkpoint inhibitors (ICI's) in the past decade has proven
transformative in the area of immuno-oncology. The PD-1/PD-L1 axis has been particularly …

Background We investigated the combined effects of sarcopenia and inflammation on
outcomes in patients with HCC treated with nivolumab. Materials and Methods We reviewed …